Last mentioned: Mar 18, 2026
PDUFA Date
Target date for FDA decision on INO-3107 accelerated approval.
Platform Modernization
LivePerson expects to complete its multiyear platform modernization.
BLA Acceptance
FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.
Inovio Cash Position
Company ends the year with $94.1 million in cash.
Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.
This page surfaces every story mentioning Jacqueline Shea across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Jacqueline Shea was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |